GM 1892

Drug Profile

GM 1892

Latest Information Update: 07 Feb 2001

Price : $50

At a glance

  • Originator Glycomed
  • Class Anti-ischaemics
  • Mechanism of Action Glycosaminoglycan inhibitors; Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued End-organ damage; Reperfusion injury

Most Recent Events

  • 07 Feb 2001 Discontinued-Preclinical for End-organ damage in USA (Unknown route)
  • 07 Feb 2001 Discontinued-Preclinical for Reperfusion injury in USA (Unknown route)
  • 28 Apr 1998 Preclinical development for Reperfusion injury in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top